Vistagen to Cut Workforce by 20% in March, Citing Cash Management
Key Facts
Vistagen said it implemented a reduction of about 20% of its workforce on March 5, 2026, a move it said was aimed at managing cash prudently while prioritizing the execution of ongoing clinical trials. The company filed its disclosure with the U.S. Securities and Exchange Commission on March 11, making the decision a measure announced in March, not a new reduction in October. The move is tied to the PALISADE program for fasedienol, which the company is developing to treat acute social anxiety disorder. The company said the purpose was "to manage cash prudently while prioritizing the effective execution of ongoing clinical trials."
According to the quarterly report, the board approved a reduction of about 20% of the workforce in March, and the company had 41 full-time employees as of June 30, 2026. Vistagen said affected employees may be eligible for cash severance and temporary health coverage, subject to eligibility requirements, the choice of coverage and execution of an effective separation agreement. The company said it expected the reduction costs to be immaterial, while acknowledging that it could incur additional unforeseen costs related to the move. The disclosure places the decision among the company’s announced cash management measures, without specifying expected operating savings.
In the quarter ended June 30, 2026, research and development expenses fell to $10.9 million from $11.7 million in the comparable period of 2025. The company attributed the change mainly to fasedienol development activities aimed at U.S. registration, manufacturing and development of its drug candidates. General and administrative expenses also declined to $3.9 million, compared with $4.4 million a year earlier, and the company said it expected them to remain at current levels as a result of cash conservation measures following the March reduction. Net loss narrowed to $13.0 million from $15.1 million in the corresponding quarter of 2025. But the same report said the company used $14.7 million in cash in operations during the quarter and expected losses and negative cash flows to continue for the foreseeable future.
In its August report, Vistagen said substantial doubt existed about its ability to continue as a going concern, as it could not confirm that cash and cash equivalents and marketable securities would be sufficient to fund operations for more than 12 months from the report’s issuance date. This warning places the March outlook that liquidity would cover operations through 2027 in a more cautious context, given the different timing of the two disclosures. In March, the company expected liquidity to extend into 2027; in August, it reported uncertainty about whether funding would last beyond 12 months from the report date. This underscores the importance of managing available resources alongside continued clinical development.
In March, the company had expected preliminary results from the Phase 3 PALISADE-4 trial in the first half of 2026. However, Vistagen announced on June 30 that fasedienol did not achieve statistically significant improvement in the primary and secondary endpoints; it reported in a subsequent analysis of patients with very severe social anxiety a nominally statistically significant improvement in the primary endpoint. In September, it announced positive preliminary data from the trial’s open-label extension and said fasedienol nasal spray was well tolerated when used as needed for up to 12 months, with no new drug safety findings. It also announced in August that it planned to engage with the U.S. Food and Drug Administration during the current quarter regarding a potential Phase 3 path for the drug. On October 20, it said it had selected GATC Health to apply predictive AI modeling to its drug programs, with the aim of providing additional insights for protocol development and resource allocation.